Our group is interested in identifying and characterizing radiolabelled surrogate markers of cancer hallmarks which can be utilized as imaging biomarkers. Promising markers will be used for molecular imaging in preclinical tumor models and in the human disease using dedicated preclinical and clinical PET or PET/CT devices. Based on translational studies, the most appropriate tracer will be selected, enabling the sensitive detection of cancers as well as early response monitoring and prediction of individual prognosis. We further aim at correlating uptake of various radiotracers with the underlying biology and metabolism. This should provide a means for patient- and disease-specific selection of PET radiotracers. The ultimate goal is to use non-invasive imaging for selecting the most effective treatment strategy, resulting in superior outcome and reduced side effects.
Herrmann K, Dahlbom M, Nathanson D, Wei L, Radu C, Chatziioannou A, Czernin J: Evaluation of the Genisys4, a Bench-Top Preclinical PET Scanner. J Nucl Med 2013, 54(7):1162-1167.
Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W: Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol 2013.
Al-Ibraheem A, Buck AK, Benz MR, Rudert M, Beer AJ, Mansour A, Pomykala KL, Haller B, Juenger H, Scheidhauer K, Schwaiger M, Herrmann K: (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Cancer 2013, 119(6):1227-1234.
Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC: 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res 2012, 18(7):2024-2031.
Herrmann K, Wieder HA, Buck AK, Schoffel M, Krause BJ, Fend F, Schuster T, Meyer zum Buschenfelde C, Wester HJ, Duyster J, Peschel C, Schwaiger M, Dechow T: Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007, 13(12):3552-3558.